Insider · CIK 0001732369
Jasbir Seehra
Files at KROS (Keros Therapeutics, Inc.). First filing Feb 20, 2026, latest Feb 20, 2026.
In brief
Jasbir Seehra files SEC Form 4 as CEO and director at KROS (Keros Therapeutics, Inc.). Since Feb 20, 2026, Jasbir Seehra has reported 0 open-market buys worth $0 and 1 open-market sell worth $113k, the latest filed on Feb 20, 2026.
A track record needs three past buys with six months of prices behind them; Jasbir Seehra has 0, so none is measured yet.
The newest scored trade: sold $113k of KROS on Feb 19, 2026, filed Feb 20, 2026, scored 50 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $113k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KROS: Keros Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Keros Therapeutics, Inc. | $113k 7,015 shares | -2% | +73% from low-24% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | KROS Keros Therapeutics, Inc. | MOption exercise Common Stock | +55,000 | $0.30 | $17k | 440,708 | Apr 6, 2026 |
| Apr 2, 2026 | KROS Keros Therapeutics, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative | -55,000 | $0.00 | $0 | 197,444 | Apr 6, 2026 |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +217,000 | $0.00 | $0 | 217,000 | Feb 26, 2026 |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 26, 2026 |
| Feb 19, 2026 | KROS Keros Therapeutics, Inc. | SOpen-market sale Common Stock | -7,015 | $16.17 | $113k | 385,708 | Feb 20, 2026 |
| Jan 7, 2026 | KROS Keros Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +62,500 | $0.00 | $0 | 62,500 | Jan 9, 2026 |
| Sep 3, 2025 | KROS Keros Therapeutics, Inc. | AGrant or award Common Stock | +90,500 | $0.00 | $0 | 392,723 | Sep 5, 2025 |
| Apr 4, 2025 | KROS Keros Therapeutics, Inc. | MOption exercise Common Stock | +49,367 | $0.30 | $15k | 302,223 | Apr 7, 2025 |
| Apr 4, 2025 | KROS Keros Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -49,367 | $0.00 | $0 | 252,444 | Apr 7, 2025 |
Questions about Jasbir Seehra
Answered from the filings on this page, as of the latest one.
Is Jasbir Seehra buying or selling?
In the last 12 months Jasbir Seehra reported 0 open-market buys worth $0 and 1 open-market sell worth $113k on SEC Form 4; the latest was sold $113k of KROS on Feb 19, 2026. Grants, option exercises and tax withholding are not counted.
How did Jasbir Seehra's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jasbir Seehra has 0.
Where does Jasbir Seehra file Form 4?
Jasbir Seehra has filed Form 4 at KROS (Keros Therapeutics, Inc.) as CHIEF EXECUTIVE OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.